Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)
Paraesthesia, balance problems, or cognitive difficulties may persist despite normalising blood counts
I.YamamotoY.TsujiW.et al
The Role of Gut Health in Absorption Your gut is the gatekeeper of your health
US$ 24.78
US$ 23.34
US$ 29.36
US$ 27.22
US$ 26.79
